Toleranzias technology is based on disease-specific proteins. These proteins are called tolerogens and are intended to induce so-called immunological tolerance.
There is a great medical need to develop new treatment methods that can create disease-specific tolerance in the immune system as a means of treating various autoimmune diseases. Toleranzia develops tolerogens – a new treatment method for inducing immunological tolerance in patients with autoimmune disease.
Toleranzia’s tolerogens are highly flexible – the disease-specific part may be adapted for a variety of autoimmune diseases. Apart from Toleranzia’s primary indication, myasthenia gravis, the technology portfolio has been evaluated in three other indications – positive treatment effects have been achieved in relevant animal models of diabetes type 1, rheumatoid arthritis, and multiple sclerosis. This validates Toleranzia’s technology as a technology portfolio with broad application potential for the development of new therapies for autoimmune diseases.
Toleranzia’s tolerogen therapy is disease-specific and affects only the part of the immune system which is linked to the disease while other parts of our immune system, such as the ability to protect against infectious diseases and the ability to prevent cancer development, which is central to our health, remain intact. Toleranzia’s targeted therapy will therefore not lead to the negative side effects that current unspecific therapies cause patients. As a result of Toleranzia’s treatment, the disease-specific components will be tolerated by the immune system and their role in the body will be normalized.